The Pharmacy Times® Chronic Lymphocytic Leukemia Resource Center is a comprehensive resource for clinical news and expert insights on treatments for chronic lymphocytic leukemia.
December 8th 2024
The phase 3 AMPLIFY trial demonstrates that fixed-duration regimens of acalabrutinib and venetoclax, with or without obinutuzumab, significantly improve progression-free survival and deliver manageable safety profiles compared to chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia (CLL).
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
1.0 Credits / Hematologic Cancer, Oncology
View More
Revolutionizing Multiple Myeloma Care: CAR T-Cell Therapy, Bispecific Antibodies, and Patient-Centered Strateg...
1.0 Credit / Oncology, Hematologic Cancer
View More
Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists
1.0 Credit / Hematologic Cancer, Oncology
View More
Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
1.0 Credit / Hematologic Cancer, Oncology
View More
Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: ...
1.0 Credit / Hematologic Cancer
View More
Navigating Chronic Lymphocytic Leukemia Therapy and Cardiovascular Comorbidities: Clinical Recommendations and...
1.0 Credit / Hematologic Cancer
View More
Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based C...
1.0 Credit / Hematologic Cancer, Oncology
View More
Balancing Innovation and Implementation: A Comprehensive Approach to CAR T, Bispecific Antibodies, and Operati...
1.0 Credit / Hematologic Cancer, Oncology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes: Bridging Clinical Innovation and Pract...
1.0 Credit / Hematologic Cancer, Oncology
View More
Finding Balance Between Advancement and Application: A Guide for Community Oncology Pharmacists on CAR T-Cell ...
0.75 Credit / Oncology, Hematologic Cancer
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodi...
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Manage...
1.5 Credits / Hematology, Hematologic Cancer, Oncology
View More
Navigating Long-Term Toxicities of CAR T-Cell Therapy: Educational Insights for Oncology Pharmacists
1.25 Credits / Oncology, Hematologic Cancer
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Overcoming Disparities in Multiple Myeloma Treatment: Empowering Pharmacists to Drive Change
1.0 Credit / Health Equity, Diversity & Inclusion, Hematologic Cancer, Hematology, Oncology
View More
Navigating Treatment Evolution in Myelofibrosis: Oncology Pharmacist's Strategies for JAK Inhibitor Optimizati...
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatme...
1.0 Credit / Hematologic Cancer, Oncology
View More
SimulatEd™: Patient-Centered Care to Improve Outcomes in Chronic Lymphocytic Leukemia
1.0 Credit / Hematologic Cancer
View More
Cytokine Release Syndrome With Bispecific Antibodies: A Pharmacist's Guide to Safe Management
1.0 Credit / Hematologic Cancer, Lung Cancer, Oncology
View More
A Pharmacist's Guide to the Safe and Effective Management of BTK and BCL-2 inhibitors in Chronic Lymphocytic L...
1.0 Credit / Hematologic Cancer, Oncology
View More
Closing Gaps in CLL Care: Managed Care Insights and Strategies
1.5 Credit / Hematologic Cancer, Oncology
View More
Guiding Bispecific Antibody Use in Non-Hodgkin Lymphoma: Integrating Evidence and Enhancing Care
1.5 Credits / Hematologic Cancer, Hematology, Oncology
View More
Navigating the New Wave in Targeted Therapies for Acute Myeloid Leukemia: A Focus on IDH and FLT3 Mutations
1.0 Credit / Hematologic Cancer, Oncology
View More
This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.
Read More
Covalent BTK Inhibitors: A Review of the Evidence in Chronic Lymphocytic Leukemia
This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.
Read More
Study Suggests Base-Edited T Cells Could Minimize Immunotherapy Complications in Leukemia Treatment
September 14th 2023The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.
Read More
Case Study: New Treatment Options for Patients With Chronic Lymphocytic Leukemia
August 2nd 2023With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.
Read More